India’s Drug-Price Agency Rankles Drug Makers
This article was originally published in PharmAsia News
Executive Summary
India's drug-pricing regulator is flexing its muscles in going after drug makers for allegedly charging more for their products than rules allow. The National Pharmaceutical Pricing Authority has been going after drug makers even as the two entities are involved in court litigation over the price limits. The fight between the two entities over price caps has led to a stack of court cases, partly because of a concern of a conflict between regulations and policy. But the chief problem may be a lack of coordination between the NPPA and the country's regulator of quality, the Drug Controller General of India. (Click here for more